HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis methods and biological features of the most potent dual NO-HDAC inhibitor in each category with the intention of assisting in the synthesis and optimization of new drug-like compounds for diverse diseases. Based on studies done so far, NO-HDAC dual inhibitors have displayed satisfactory results against wound healing (3), heart hypertrophy (3), inflammatory, cardiovascular, neuromuscular illnesses (11a-11e) and cancer (6a-6o, 9a-9d, 10a-10d, 16 and 17). NO-HDAC dual inhibitors can have high therapeutic potential for various diseases due to their new properties, NO properties, HDAC inhibitor properties and also due to the effects of NO on HDAC enzymes.

HDAC 抑制剂和 NO 供体均已在多种疾病中显示出独立的广泛治疗潜力。博雷托等人。2013 年首次提出了 NO-HDAC 双抑制剂这一话题，作为一个有吸引力的新话题。在这里，我们收集了所有合成的 NO-HDAC 双抑制剂的一般结构，先导化合物，合成方法和每个类别中最有效的双 NO-HDAC 抑制剂的生物学特征，旨在协助合成和优化新的类药物多种疾病的化合物。根据迄今为止所做的研究，NO-HDAC 双重抑制剂对伤口愈合 ( 3 )、心脏肥大 ( 3 )、炎症、心血管、神经肌肉疾病 ( 11a-11e ) 显示出令人满意的结果) 和癌症 ( 6a-6o、9a-9d、10a-10d、16和17 )。NO-HDAC双重抑制剂由于其新的特性、NO特性、HDAC抑制剂特性以及由于NO对HDAC酶的影响而对各种疾病具有很高的治疗潜力。